Novavax, Inc. (NVAX) is slated to report 2Q 2015 earnings after the close on Monday, August 10th. The clinical-stage vaccine company is expected to report revenue of $9.9 million. Similarly, the EPS is projected to come at loss of ($0.09). A year ago, Novavax lost ($0.08) a share. The Street’s estimates for the quarter represents a year-over-year EPS loss of 11%.
As a quick reminder, Novavax reported 1Q/15 EPS loss of ($0.10), $0.01 better than the Street’s consensus estimate. Revs rose 32% YoY to $9.9 million versus the $9.7 million consensus.
On trading measures, Novavax, Inc., currently valued at $2.90 billion, has a median Wall Street price target of $15.00 with a high target of $18.00. In the past 52 weeks, shares of Gaithersburg, Maryland-based company have traded between a low of $3.92 and a high of $13.12 with the 50-day MA and 200-day MA located at $11.55 and $9.29 levels, respectively. Additionally, shares of NVAX have a Relative Strength Index (RSI) and MACD indicator of 41.78 and -0.48, respectively.
The closing price of NVAX on August 7 was $10.83, representing one year return of about 157%. During the same period, the S&P 500 increased 7.26%